Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says Bio Vitos, a company that sells omega 3 tablets and in which Craven House owns a 24.5% stake, enters into an agreement to buy an 88% stake in Hemcheck Sweden AB, a company focused on detecting hemolyzed blood samples. Hemolyzed means red blood cells in a sample burst, usually rendering it unable to yield a test result. Bio Vitos will pay Hemcheck SEK5.2 million, around £407,249, in cash for business and assets.
Current stock price: $0.35
12-month change: up 59%
Copyright 2023 Alliance News Ltd. All Rights Reserved.